<DOC>
	<DOCNO>NCT00276003</DOCNO>
	<brief_summary>Primary objective - Assess response rate patient recurrent refractory B-cell NHL Hodgkins disease , treat combination gemcitabine irinotecan . Secondary objective - Assess progression free survival patient treat regimen . - Assess toxicity regimen group patient .</brief_summary>
	<brief_title>INST Phase II Trial Gemcitabine Irinotecan Patients With Relapsed Refractory Lymphoma .</brief_title>
	<detailed_description>The purpose study see well patient relapse refractory lymphoma respond treatment Gemcitabine Irinotecan . Patients study take part relapse refractory lymphoma . Additionally , study assess treatment-related side effect time disease progression recurrence .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>1 . Patients histologic diagnosis nonHIV relate Bcell NHL Hodgkins disease eligible . 2 . Patients document evidence refractory relapse NHL Hodgkins disease inclusion . 3 . Patient receive 1 prior chemotherapeutic regimen relapse , complete last course treatment least 3 week prior enrollment . 4 . The patient must bidimensionally measurable evaluable disease . 5 . Age &gt; 18 year . 6 . ECOG Performance status &lt; 2 7 . Informed consent . 8 . ANC &gt; 1.5 , platelet count &gt; 100K , creatinine &lt; 2.0 , bilirubin &lt; 3 9 . Female patient must negative pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Lymphoma-Non Hodgkins</keyword>
	<keyword>Phase II</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Irinotecan</keyword>
</DOC>